Daiichi Sankyo reports positive Tribenzor trial data

Daiichi Sankyo has published positive data from a new clinical trial of Tribenzor, its treatment for hypertension.

The company has reported data from a phase III clinical trial called Trinity, which evaluated the combination therapy option among 2,492 patients to gauge its efficacy in maintaining blood pressure reductions.

It was found that after 52 weeks, the treatment was well-tolerated and clinically effective, regardless of the age, ethnic background or diabetes status of the patients involved.

Tribenzor combines olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide and is designed to be administered once daily.

Dr Suzanne Oparil, professor of medicine and physiology and biophysics at the University of Alabama School of Medicine, said: "This analysis shows that long-term blood pressure control can be achieved safely and effectively across all studied dosing strengths with a triple combination therapy regardless of age."

Currently, Daiichi Sankyo is carrying out a phase III study of ARQ 197, a non-small cell lung cancer treatment developed in partnership with ArQule.